The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | J | Antiinfectives for systemic use | |
2 | J06 | Immune sera and immunoglobulins | |
3 | J06B | Immunoglobulins | |
4 | J06BD | Antiviral monoclonal antibodies |
Code | Title | |
---|---|---|
J06BD01 | Palivizumab | |
J06BD02 | Motavizumab | |
J06BD03 | ||
J06BD04 | ||
J06BD05 | ||
J06BD06 | ||
J06BD07 | ||
J06BD08 |
Active Ingredient | Description | |
---|---|---|
Ansuvimab |
Ansuvimab is a recombinant human monoclonal antibody with antiviral activity against Zaire ebolavirus. |
|
Casirivimab and imdevimab |
Casirivimab (IgG1Îș) and imdevimab (IgG1λ) are two recombinant human monoclonal antibodies which are unmodified in the Fc regions. Casirivimab and imdevimab bind to non-overlapping epitopes of the spike protein receptor binding domain (RBD) of SARS-CoV-2. This prevents RBD binding to the human ACE2 receptor, so preventing virus entry into cells. |
|
Nirsevimab |
Nirsevimab is a recombinant neutralising human IgG1Äž long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion. |
|
Palivizumab |
Palivizumab is a humanised IgG1Îș monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains. |
|
Regdanvimab |
Regdanvimab is a recombinant human IgG1 monoclonal antibody that binds to the receptor binding domain (RBD) of the spike(s) protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection. |
|
Sotrovimab |
Sotrovimab is a dual action, engineered human IgG1 mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. It is used for the treatment of symptomatic adults and adolescents with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection. |
|
Tixagevimab and Cilgavimab |
Tixagevimab and cilgavimab are two recombinant human IgG1 monoclonal antibodies, with amino acid substitutions in the Fc regions, to extend antibody half-life and to reduce antibody effector function and potential risk of antibody-dependent enhancement of disease. Tixagevimab and cilgavimab can simultaneously bind to non-overlapping regions of the spike protein receptor binding domain (RBD) of SARS-CoV-2. Tixagevimab, cilgavimab and their combination bind to spike blocking its interaction with the human ACE2 receptor, resulting in a blockade of virus entry. |
Title | Information Source | Document Type | |
---|---|---|---|
BEYFORTUS Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
EBANGA Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
EVUSHELD Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
REGKIRONA Concentrate for solution for infusion | MPI, EU: SmPC | ||
REGKIRONA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
RONAPREVE Solution for injection/infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SYNAGIS Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
XEVUDY Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |